Candel Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Candel Therapeutics Inc 's ROA in the second quarter of 2026?
Candel Therapeutics Inc recorded a cumulative net loss of $-89 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -56.24%.

However, within the Healthcare sector 594 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3809, from total ROA ranking in the first quarter of 2026 at 4386.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	98.2 %	110.54 %	17.15 %	329.88 %	300.11 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-89	-54	-38	-23	-22
Return On Assets (TTM)	-56.24 %	-41.42 %	-36.4 %	-22.69 %	-26.81 %
CADL's Total Ranking	# 3809	# 4386	# 3603	# 3721	# 4297
Total Assets (TTM) in million	210	202	125	92	106
Seq. Total Assets Change	4.02 %	61.28 %	35.35 %	-12.71 %	10.49 %
Seq. Net Income Change	-	-	-	-	-

CADL's 5 Years Annual ROA >> Back to CADL Management Effectiveness >> Compare CADL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 81
Sector	# 595
Overall	# 3960

Return On Assets Statistics
High	Average	Low
-1.1 %	-56.05 %	-173.39 %
(Mar 31 2022)		(Sep 30 2024)

News about Candel Therapeutics Inc Return on Assets ROA

Candel Therapeutics Taps Pancreatic Cancer Authority Elizabeth Jaffee Amid Financial Struggles: Searching for Breakthroughs in a Challenging Landscape,

Candel Therapeutics Appoints Pancreatic Cancer Expert Amid Struggles: A New Chapter or an Uphill Battle?NEEDHAM, Mass.—In a move that signals both promise and urgency, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical-stage biopharmaceutical company, has appointed Dr. Elizabeth M. Jaffee, an internationally renowned expert in cancer immunology and pancreatic cancer, to its Research Advisory Board (RAB). This decision comes at a pivotal time for the company, which is focused on developing cutting-edge immunotherapies to combat one of the deadliest forms of cancer—borderline resectable pancreatic cancer.Dr. Jaffee s expertise will be crucial as Candel couples its ambitious plans with the harsh reality of its financial landscape. The company reported a staggering cumulative net loss of $55 million for the 12 months leading up to the fourth quarter of 2024, resulting in a dismal return on assets (ROA) of -118.61%. Such figures paint a troubling picture, especially when viewed against the backdrop of a healthcare sector where 529 other companies boast better ROA. On the surface, Jaffee s appointment appears timely, redirecting attention to the promising potential of Candel s research endeavors. This is particularly relevant in light of the company s earlier announcement detailing the significant advancements made in their Phase 3 trial of CAN-2409, a viral immunotherapy aimed at localized prostate cancer. The trial results indicated that CAN-2409 met its primary endpoint by significantly improving disease-free survival (DFS) rates among participants—a critical benchmark in the ongoing battle against cancer recurrence.

Candel Therapeutics Inc (CADL) Navigating Market Fluctuations and Executive Stock Sales

Candel Therapeutics Inc (NASDAQ: CADL) has been a point of interest for investors and analysts alike over the past few weeks, marked by notable fluctuations in stock performance and significant insider trading activity. As we delve into the specifics surrounding Candel Therapeutics, we uncover the implications of recent quarterly movements, executive decisions, and market sentiments that outline the company s current standing in the competitive biotech landscape. Quarterly Stock Movements: A Roller Coaster RideThe recent performance data of Candel Therapeutics paints a picture of volatility that has been present in the stock market. Over the last week, shares of CADL experienced a sharp decline of 10.15% . However, this short-term dip contrasts with a more positive trajectory observed over the past quarter, where the stock rose by 18.23% . Additionally, a cautious 8.44% increase was noted within the last month. This fluctuation emphasizes the inherent volatility of biotech stocks as they often respond to broader market trends, investor sentiment, and company-specific news.

Financial Statements
Candel Therapeutics Inc 's Assets	$ 210 million	CADL's Balance sheet
Candel Therapeutics Inc 's Income	$ -39 million	Quarterly CADL's Income Statement
CADL's Income by Division		See CADL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	17.15 %	159.38 %	-46.05 %	-14.39 %	-
Total Assets in million	125	107	41	76	89
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-38	-55	-38	-19	-36
Annual Return On Assets	-30.5 %	-51.63 %	-92.08 %	-24.61 %	-40.5 %

CADL's 5 Years Annual ROA >> Back to CADL Management Effectiveness >> Compare CADL ROA to its Competitors

More Return On Assets Ratios
CADL's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CADL's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CADL's Competitors
Subscribers only: Roa for Candel Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CADL's Customers

You may also want to know
CADL's Roi	CADL's Inventory Turnover Ratio	CADL's Growth Rates	CADL's Dividend Comparisons
	CADL's Profitability Ratios	CADL's Asset Turnover Ratio	CADL's Dividend Growth
CADL's Roe	CADL's Valuation Ratios	CADL's Financial Strength Ratios	CADL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:25:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.